Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [41] Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months
    A. D. Anastasilakis
    S. A. Polyzos
    P. Makras
    A. Gkiomisi
    I. Bisbinas
    A. Katsarou
    A. Filippaios
    C. S. Mantzoros
    [J]. Osteoporosis International, 2014, 25 : 1633 - 1642
  • [42] EFFECTS OF ONE-YEAR CYCLICAL TREATMENT WITH CLODRONATE ON POSTMENOPAUSAL BONE LOSS
    GIANNINI, S
    DANGELO, A
    MALVASI, L
    CASTRIGNANO, R
    PATI, T
    TRONCA, R
    LIBERTO, L
    NOBILE, M
    CREPALDI, G
    [J]. BONE, 1993, 14 (02) : 137 - 141
  • [43] RETRACTED ARTICLE: Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal DysfunctionA Retrospective Study
    Jun Iwamoto
    Yoshihiro Sato
    Mitsuyoshi Uzawa
    Tsuyoshi Takeda
    Hideo Matsumoto
    [J]. Drugs & Aging, 2012, 29 : 133 - 142
  • [44] Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study
    Senn, C.
    Guenther, B.
    Popp, A. W.
    Perrelet, R.
    Hans, D.
    Lippuner, K.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (07) : 1945 - 1951
  • [45] A Longitudinal HR-pQCT Study of Alendronate Treatment in Postmenopausal Women With Low Bone Density: Relations Among Density, Cortical and Trabecular Microarchitecture, Biomechanics, and Bone Turnover
    Burghardt, Andrew J.
    Kazakia, Galateia J.
    Sode, Miki
    de Papp, Anne E.
    Link, Thomas M.
    Majumdar, Sharmila
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (12) : 2282 - 2295
  • [46] Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis
    Iwamoto, J
    Takeda, T
    Sato, Y
    Uzawa, M
    [J]. YONSEI MEDICAL JOURNAL, 2004, 45 (04) : 676 - 682
  • [47] Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone
    Hu, JH
    Ding, M
    Soballe, K
    Bechtold, JE
    Danielsen, CC
    Day, JS
    Hvid, I
    [J]. BONE, 2002, 31 (05) : 591 - 597
  • [48] Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study
    C. Senn
    B. Günther
    A. W. Popp
    R. Perrelet
    D. Hans
    K. Lippuner
    [J]. Osteoporosis International, 2014, 25 : 1945 - 1951
  • [49] Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: A three-year study
    Popp, Albrecht W.
    Guler, Sabina
    Lamy, Olivier
    Senn, Christoph
    Buffat, Helene
    Perrelet, Romain
    Hans, Didier
    Lippuner, Kurt
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (03) : 449 - 454
  • [50] Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: A 5-year follow-up
    Tuppurainen, Marjo
    Harma, Kirsi
    Komulainen, Marja
    Kiviniemi, Vesa
    Kroger, Heikki
    Honkanen, Risto
    Alhava, Esko
    Jurvelin, Jukka
    Saarikoski, Seppo
    [J]. MATURITAS, 2010, 66 (04) : 423 - 430